safety outcomes of darolutamide vs apalutamide and enzalutamide in nmcrpc
Published 4 years ago • 1.2K plays • Length 2:38Download video MP4
Download video MP3
Similar videos
-
1:57
aramis: efficacy and safety of darolutamide in nmcrpc
-
12:42
pca commentary - nmcrpc and androgen receptor inhibition: enzalutamide, apalutamide and darolutamide
-
2:45
interaction of darolutamide with substrates of cyps and p-gp
-
1:55
awaiting key results for enzalutamide and apalutamide in nmcrpc
-
8:09
comparing apalutamide and enzalutamide in real-world treatment of mcspc
-
12:08
new fda approval: darolutamide for hormone-sensitive disease | mark scholz, md | pcri
-
6:46
what is nubeqa for prostate cancer and how does it work? | ask a prostate expert, mark scholz, md
-
5:19
xtandi patient stories
-
5:12
darolutamide for nmcrpc: results of the aramis trial
-
5:20
apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer.
-
1:03
kim n. chi, md, outlines the safety profile of apalutamide
-
3:40
this is spartan! apalutamide treatment for nmcrpc
-
4:36
nonmetastatic crpc: considerations for apalutamide
-
2:46
aramis: darolutamide in patients with nmcrpc
-
2:50
prosper: enzalutamide vs. placebo for nmcrpc
-
6:42
titan trial
-
2:02
assessing the role of darolutamide in crpc
-
9:51
overall survival data presented at asco 2020 for nmcrpc
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
1:23
dr. saad on the safety profile of apalutamide in m0crpc
-
0:42
enzalutamide in the non-metastatic setting for crpc
-
1:44
talapro-2: exposure-safety of talazoparib enzalutamide in mcrpc